Results 171 to 180 of about 5,099,009 (221)
Some of the next articles are maybe not open access.
The Lancet Oncology, 2001
During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles.
I, Barista +2 more
openaire +2 more sources
During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles.
I, Barista +2 more
openaire +2 more sources
Treatment of Mantle-Cell Lymphoma
New England Journal of Medicine, 2022[No Abstract Available]
Burhan, Ferhanoglu +2 more
openaire +5 more sources
Current Opinion in Hematology, 2004
Mantle cell lymphoma is the B-cell lymphoma with the worst prognosis. Until now, no standard treatment has resulted in cure. Improvements in understanding of the disease are needed to advance therapeutic efforts.Pathology and immunohistochemistry can identify the subset of patients with the worse prognosis.
Francesco, Bertoni +2 more
openaire +2 more sources
Mantle cell lymphoma is the B-cell lymphoma with the worst prognosis. Until now, no standard treatment has resulted in cure. Improvements in understanding of the disease are needed to advance therapeutic efforts.Pathology and immunohistochemistry can identify the subset of patients with the worse prognosis.
Francesco, Bertoni +2 more
openaire +2 more sources
1997
MCLs are thought to arise from a subset of B cells that normally express the CD5 antigen and that reside in the mantle zone of secondary lymphoid follicles. Although expression of the CD5 antigen is also seen in small lymphocytic lymphoma and chronic lymphocytic leukemia, MCL differs from SLL/ CLL in several ways.
M A, Rodriguez, W C, Pugh
openaire +2 more sources
MCLs are thought to arise from a subset of B cells that normally express the CD5 antigen and that reside in the mantle zone of secondary lymphoid follicles. Although expression of the CD5 antigen is also seen in small lymphocytic lymphoma and chronic lymphocytic leukemia, MCL differs from SLL/ CLL in several ways.
M A, Rodriguez, W C, Pugh
openaire +2 more sources
Current Treatment Options in Oncology, 2000
Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years.
J J, Densmore, M E, Williams
openaire +3 more sources
Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years.
J J, Densmore, M E, Williams
openaire +3 more sources
Journal of Clinical Oncology, 2016
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of ...
Chan Yoon, Cheah +2 more
openaire +2 more sources
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of ...
Chan Yoon, Cheah +2 more
openaire +2 more sources
Properties of the mantle cell and mantle cell lymphoma
Current Opinion in Hematology, 2002The major lymphoid inhabitant of the follicular mantle is the mantle cell, an immunologically naïve B cell. It is the putative cell of origin of mantle cell lymphoma (MCL), the cells of which have similar morphologic, immunophenotypic, and molecular characteristics to the normal B lymphocytes of the mantle zone.
John L, Frater, Eric D, Hsi
openaire +2 more sources
Advances in Anatomic Pathology, 1998
Mantle cell lymphomas comprise 2 to 8% of non-Hodgkin's lymphoma in the United States. They occur in older adults with a distinct male predominance, who present with generalized lymphadenopathy, and often have disseminated disease at the time of diagnosis.
openaire +2 more sources
Mantle cell lymphomas comprise 2 to 8% of non-Hodgkin's lymphoma in the United States. They occur in older adults with a distinct male predominance, who present with generalized lymphadenopathy, and often have disseminated disease at the time of diagnosis.
openaire +2 more sources
Bortezomib In Mantle Cell Lymphoma
Future Oncology, 2008Mantle cell lymphoma (MCL) represents 6% of non-Hodgkin lymphomas, but is one of the most active fields of clinical investigation. Unfortunately, there is still no standard or curative therapy in MCL. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense ...
K Stephen, Suh, Andre, Goy
openaire +2 more sources
Mantle-Cell Lymphomas of the Skin
Dermatologic Clinics, 1994The skin lesions of two elderly women lead us to the diagnosis of small cleaved lymphocytic B-cell non-Hodgkin's lymphoma, TNM stage IVb after clinical staging examinations. Relapses occurred within less than 1 year. Morphology, enzymhistochemistry (alkaline phosphatase in the first case), and immunohistochemistry (CD 5 positivity in the second case ...
M L, Geerts, A M, Busschots
openaire +2 more sources